Marker Therapeutics (MRKR) Competitors

Marker Therapeutics logo
$0.85 +0.02 (+1.98%)
Closing price 04:00 PM Eastern
Extended Trading
$0.85 +0.00 (+0.09%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MRKR vs. KVAC, CRDF, XBIT, XLO, and BOLD

Should you buy Marker Therapeutics stock or one of its competitors? Marker Therapeutics's main competitors and comparable companies include Keen Vision Acquisition (KVAC), Cardiff Oncology (CRDF), XBiotech (XBIT), Xilio Therapeutics (XLO), and Boundless Bio (BOLD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Marker Therapeutics compare to Keen Vision Acquisition?

Marker Therapeutics (NASDAQ:MRKR) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Marker Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Keen Vision Acquisition's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Marker TherapeuticsN/A -60.00% -50.22%
Keen Vision Acquisition N/A N/A N/A

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Marker Therapeutics had 2 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 2 mentions for Marker Therapeutics and 0 mentions for Keen Vision Acquisition. Marker Therapeutics' average media sentiment score of 0.56 beat Keen Vision Acquisition's score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Marker Therapeutics Positive
Keen Vision Acquisition Neutral

Keen Vision Acquisition has lower revenue, but higher earnings than Marker Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marker Therapeutics$3.55M3.93-$12.16M-$0.41N/A
Keen Vision AcquisitionN/AN/AN/AN/AN/A

Marker Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 1,095.31%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Keen Vision Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Keen Vision Acquisition
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Marker Therapeutics beats Keen Vision Acquisition on 7 of the 11 factors compared between the two stocks.

How does Marker Therapeutics compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Cardiff Oncology had 12 more articles in the media than Marker Therapeutics. MarketBeat recorded 14 mentions for Cardiff Oncology and 2 mentions for Marker Therapeutics. Cardiff Oncology's average media sentiment score of 0.71 beat Marker Therapeutics' score of 0.56 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardiff Oncology
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Marker Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cardiff Oncology has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Cardiff Oncology presently has a consensus target price of $7.50, suggesting a potential upside of 786.11%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 1,095.31%. Given Marker Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Cardiff Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Marker Therapeutics has higher revenue and earnings than Cardiff Oncology. Marker Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$590K111.60-$45.85M-$0.55N/A
Marker Therapeutics$3.55M3.93-$12.16M-$0.41N/A

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Marker Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,736.49%. Marker Therapeutics' return on equity of -60.00% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-6,736.49% -111.80% -81.51%
Marker Therapeutics N/A -60.00%-50.22%

Summary

Marker Therapeutics beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

How does Marker Therapeutics compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

XBiotech's return on equity of -33.03% beat Marker Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XBiotechN/A -33.03% -31.57%
Marker Therapeutics N/A -60.00%-50.22%

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 21.1% of XBiotech shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 1,095.31%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than XBiotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBiotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Marker Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Marker Therapeutics and 1 mentions for XBiotech. Marker Therapeutics' average media sentiment score of 0.56 beat XBiotech's score of -0.61 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
XBiotech Negative
Marker Therapeutics Positive

XBiotech has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Marker Therapeutics has higher revenue and earnings than XBiotech. Marker Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A-$45.54M-$1.43N/A
Marker Therapeutics$3.55M3.93-$12.16M-$0.41N/A

Summary

Marker Therapeutics beats XBiotech on 9 of the 13 factors compared between the two stocks.

How does Marker Therapeutics compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Marker Therapeutics has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xilio Therapeutics$43.77M1.22-$35.04M-$0.40N/A
Marker Therapeutics$3.55M3.93-$12.16M-$0.41N/A

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Marker Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -20.89%. Marker Therapeutics' return on equity of -60.00% beat Xilio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xilio Therapeutics-20.89% -60.54% -24.76%
Marker Therapeutics N/A -60.00%-50.22%

In the previous week, Marker Therapeutics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 2 mentions for Marker Therapeutics and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.69 beat Marker Therapeutics' score of 0.56 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xilio Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Marker Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Xilio Therapeutics has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Xilio Therapeutics presently has a consensus target price of $16.00, indicating a potential upside of 112.20%. Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 1,095.31%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Xilio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xilio Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Marker Therapeutics beats Xilio Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to Boundless Bio?

Boundless Bio (NASDAQ:BOLD) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Marker Therapeutics' return on equity of -60.00% beat Boundless Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Boundless BioN/A -70.98% -50.99%
Marker Therapeutics N/A -60.00%-50.22%

22.4% of Marker Therapeutics shares are held by institutional investors. 23.1% of Boundless Bio shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Boundless Bio has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

In the previous week, Boundless Bio and Boundless Bio both had 2 articles in the media. Boundless Bio's average media sentiment score of 1.29 beat Marker Therapeutics' score of 0.56 indicating that Boundless Bio is being referred to more favorably in the media.

Company Overall Sentiment
Boundless Bio Positive
Marker Therapeutics Positive

Marker Therapeutics has higher revenue and earnings than Boundless Bio. Marker Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boundless BioN/AN/A-$58.20M-$2.47N/A
Marker Therapeutics$3.55M3.93-$12.16M-$0.41N/A

Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 1,095.31%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Boundless Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boundless Bio
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Marker Therapeutics beats Boundless Bio on 10 of the 12 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRKR vs. The Competition

MetricMarker TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$13.95M$4.03B$7.72B$11.68B
Dividend YieldN/A3.63%2.47%4.51%
P/E Ratio-2.1925.9032.4827.27
Price / Sales4.0115.668.385.63
Price / CashN/A22.7220.8521.62
Price / Book0.844.164.443.72
Net Income-$12.16M-$23.99M$3.51B$394.03M
7 Day Performance-10.20%-8.45%-6.54%-6.07%
1 Month Performance-17.96%-6.55%-4.93%-7.38%
1 Year Performance-15.52%-6.56%-1.68%-7.46%

Marker Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRKR
Marker Therapeutics
2.7681 of 5 stars
$0.85
+2.0%
$10.00
+1,072.1%
-12.4%$13.95M$3.55MN/A5
KVAC
Keen Vision Acquisition
N/A$11.51
flat
N/AN/A$63.37MN/AN/AN/A
CRDF
Cardiff Oncology
1.9628 of 5 stars
$0.77
-3.6%
$7.50
+871.5%
-58.9%$60.05M$590KN/A31
XBIT
XBiotech
0.8906 of 5 stars
$1.93
+1.0%
N/A-27.9%$58.85MN/AN/A87
XLO
Xilio Therapeutics
1.9307 of 5 stars
$8.68
-3.6%
$16.00
+84.4%
-25.7%$57.08M$43.77MN/A76

Related Companies and Tools


This page (NASDAQ:MRKR) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners